FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Helen McIlleron

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Drug Therapy, Combination

Co-author Network

Publications

TOP 3
Peter R Donald; S M Graham; A Ahmed; W J Burman; M F Cotton; William R Mac Kenzie; Helen McIlleron; C Mendel; S Nachman; H Simon Schaaf; J R Starke; C Wingfield; Anneke C Hesseling
Requirements for the clinical evaluation of new anti-tuberculosis agents in children.
E H Decloedt; P Denti; Helen McIlleron; J Mwansa-Kambafwile; M Rangaka; Peter Smith; J-S van der Walt; L Wiesner; Robert J Wilkinson; Gary Maartens
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
Emmanuel Chigutsa; Paolo Denti; Carl M J Kirkpatrick; Gary Maartens; Helen McIlleron; Kashyap Patel; Marianne Visser; Mats O Karlsson
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Helen McIlleron (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter R Donald; S M Graham; A Ahmed; W J Burman; M F Cotton; William R Mac Kenzie; Helen McIlleron; C Mendel; S Nachman; H Simon Schaaf; J R Starke; C Wingfield; Anneke C Hesseling
Requirements for the clinical evaluation of new anti-tuberculosis agents in children.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013;17(6):794-9.
2013: E H Decloedt; P Denti; Helen McIlleron; J Mwansa-Kambafwile; M Rangaka; Peter Smith; J-S van der Walt; L Wiesner; Robert J Wilkinson; Gary Maartens
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013;17(3):333-5.
2013: Emmanuel Chigutsa; Paolo Denti; Carl M J Kirkpatrick; Gary Maartens; Helen McIlleron; Kashyap Patel; Marianne Visser; Mats O Karlsson
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
Antimicrobial agents and chemotherapy 2013;57(2):789-95.
2012: Chao Zhang; Paolo Denti; Mats O Karlsson; Yuan Ren; Peter Smith; Jan-Stefan van der Walt; Helen McIlleron
Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring.
Therapeutic drug monitoring 2012;34(4):481-4.
2012: Simbarashe P Zvada; Paolo Denti; Hennie Geldenhuys; Willem Hanekom; Thomas Harrison; Mark Hatherill; Amina Jindani; Sandra Meredith; Ulrika S H Simonsson; Danelle van As; Lubbe Wiesner; Helen McIlleron
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Antimicrobial agents and chemotherapy 2012;56(8):4471-3.
2012: J Mirjam Oudijk; A Sarah Walker; Chifumbe Chintu; Adrian Cook; Diana M Gibb; Helen McIlleron; Concepta Merry; Veronica Mulenga; David M Burger
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
AIDS (London, England) 2012;26(12):1523-8.
2012: Emmanuel Chigutsa; Joe Harding; William R Mac Kenzie; Helen McIlleron; Sandra Meredith; Prashini Moodley; Nesri Padayatchi; Marc Weiner; Lubbe Wiesner; Carl M J Kirkpatrick
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
Antimicrobial agents and chemotherapy 2012;56(7):3857-63.
2012: Helen McIlleron; Thuli Mthiyane; Catherine Connolly; Paolo Denti; Alexander Pym; Wasima Rida; Roxana Rustomjee; Peter J Smith; Mahnaz Vahedi; Philip C Onyebujoh
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Antimicrobial agents and chemotherapy 2012;56(6):3232-8.
2012: Chao Zhang; Ulrika S H Simonsson; Eric Decloedt; Paolo Denti; Mats O Karlsson; Gary Maartens; Helen McIlleron
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.
British journal of clinical pharmacology 2012;73(5):758-67.
2012: Wynand Smythe; Oumou Bah Sow; Peter Smith; Mame Bocar Lo; Martin Gninafon; Richard John Horton; Akash Khandelwal; Christian Lienhardt; Helen McIlleron; Corinne Merle; Piero L Olliaro; Roxana Rustomjee; Ulrika S H Simonsson
A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.
Antimicrobial agents and chemotherapy 2012;56(4):2091-8.
2012: Phumla Z Sinxadi; Peter J Smith; Joel A Dave; Naomi S Levitt; Helen McIlleron; Gary Maartens
Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study.
AIDS research and therapy 2012;9(1):32.
2012: Eric H Decloedt; Gary Maartens; Concepta Merry; Peter Smith; Funeka Bango; Helen McIlleron
The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
PloS one 2012;7(3):e32173.
2012: Chao Zhang; Ulrika S H Simonsson; Mats O Karlsson; Helen McIlleron; Yuan Ren; Jan-Stefan van der Walt; Paolo Denti
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Antiviral therapy 2012;17(1):25-33.
2012: James A Seddon; Peter R Donald; Anneke C Hesseling; Ben J Marais; Helen McIlleron; Charles A Peloquin; H Simon Schaaf
Paediatric use of second-line anti-tuberculosis agents: a review.
Tuberculosis (Edinburgh, Scotland) 2012;92(1):9-17.
2011: Emmanuel Chigutsa; Paolo Denti; Deirdre Egan; Nicholas H G Holford; Gary Maartens; Andrew Owen; Sudeep Pushpakom; Peter J Smith; Elizabeth C Swart; Marianne E Visser; Helen McIlleron
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
Antimicrobial agents and chemotherapy 2011;55(9):4122-7.
2011: Siv Jönsson; Mats O Karlsson; Alistair Davidse; Ulrika S H Simonsson; Peter Smith; Jan-Stefan Van der Walt; Justin Wilkins; Helen McIlleron
Population pharmacokinetics of ethambutol in South African tuberculosis patients.
Antimicrobial agents and chemotherapy 2011;55(9):4230-7.
2011: Eric H Decloedt; Helen McIlleron; Concepta Merry; Catherine Orrell; Peter Smith; Gary Maartens
Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
Antimicrobial agents and chemotherapy 2011;55(7):3195-200.
2011: Justin J Wilkins; Peter J Smith; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Ulrika S H Simonsson
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.
British journal of clinical pharmacology 2011;72(1):51-62.
2011: Gert van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.
Journal of acquired immune deficiency syndromes (1999) 2011;56(4):333-9.
2011: Helen McIlleron; Marianne Willemse; H Simon Schaaf; Peter John Smith; Peter R Donald
Pyrazinamide plasma concentrations in young children with tuberculosis.
The Pediatric infectious disease journal 2011;30(3):262-5.
2011: Helen McIlleron; Yuan Ren; James Nuttall; Lee Fairlie; Helena Rabie; Mark Cotton; Brian Eley; Tammy Meyers; Peter J Smith; Concepta Merry; Gary Maartens
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
Antiviral therapy 2011;16(3):417-21.
2010: Doaa Elsherbiny; Yuan Ren; Helen McIlleron; Gary Maartens; Ulrika S H Simonsson
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
European journal of clinical pharmacology 2010;66(10):1017-23.
2010: Zhenkun Ma; Christian Lienhardt; Helen McIlleron; Andrew J Nunn; Xiexiu Wang
Global tuberculosis drug development pipeline: the need and the reality.
Lancet 2010;375(9731):2100-9.
2009: Helen McIlleron; Marianne Willemse; Cedric J Werely; Gregory D Hussey; H Simon Schaaf; Peter J Smith; Peter R Donald
Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(11):1547-53.
2009: Yuan Ren; James Nuttall; Brian Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen McIlleron
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
Journal of acquired immune deficiency syndromes (1999) 2009;50(5):439-43.
2009: Karen Cohen; Alison Grant; Collet Dandara; Helen McIlleron; Lindiwe Pemba; Katherine Fielding; Salome Charalombous; Gavin Churchyard; Peter Smith; Gary Maartens
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
Antiviral therapy 2009;14(5):687-95.
2009: H Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter R Donald
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.
BMC medicine 2009;7():19.
2008: Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
Antimicrobial agents and chemotherapy 2008;52(6):2138-48.
2008: Yuan Ren; James Nuttall; Claire Egbers; Brian Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen McIlleron
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
Journal of acquired immune deficiency syndromes (1999) 2008;47(5):566-9.
2008: Karen Cohen; Gilles Van Cutsem; Andrew Boulle; Helen McIlleron; Eric Goemaere; Peter J Smith; Gary Maartens
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
The Journal of antimicrobial chemotherapy 2008;61(2):389-93.
2007: Helen McIlleron; Jennifer Norman; Thomas P Kanyok; P Bernard Fourie; Richard John Horton; Peter J Smith
Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.
The Journal of antimicrobial chemotherapy 2007;60(6):1398-401.
2007: Dominique J Pepper; Graeme Meintjes; Helen McIlleron; Robert J Wilkinson
Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery.
Drug discovery today 2007;12(21-22):980-9.
2007: Helen McIlleron; Marcia L Watkins; Peter I Folb; Stanley R Ress; Robert J Wilkinson
Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis.
Tuberculosis (Edinburgh, Scotland) 2007;87(6):557-64.
2007: Helen McIlleron; Graeme Meintjes; William Burman; Gary Maartens
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
The Journal of infectious diseases 2007;196 Suppl 1():S63-75.
2007: A H Diacon; R F Patientia; A Venter; Paul D van Helden; Peter J Smith; Helen McIlleron; J Stefan Maritz; Peter R Donald
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
Antimicrobial agents and chemotherapy 2007;51(8):2994-6.
2007: Yuan Ren; James Nuttall; Claire Egbers; Brian Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen McIlleron
High prevalence of subtherapeutic plasma concentrations of efavirenz in children.
Journal of acquired immune deficiency syndromes (1999) 2007;45(2):133-6.
2007: Gary A Gabriels; Helen McIlleron; Peter J Smith; Peter I Folb; P Bernard Fourie
Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2007;11(2):181-8.
2006: Julie A Simpson; Tsiri Agbenyega; Karen I Barnes; Gianni Di Perri; Peter I Folb; Melba Gomes; Sanjeev Krishna; Srivicha Krudsood; Sornchai Looareesuwan; Sharif Mansor; Helen McIlleron; Raymond Miller; Malcolm E Molyneux; James Mwenechanya; Visweswaran Navaratnam; François Nosten; Piero Olliaro; Lorrin Pang; Isabela Ribeiro; Madalitso Tembo; Michele van Vugt; Steve Ward; Kris Weerasuriya; Kyaw Win; Nicholas J White
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients.
PLoS medicine 2006;3(11):e444.
2006: Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.
European journal of clinical pharmacology 2006;62(9):727-35.
2006: Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
Antimicrobial agents and chemotherapy 2006;50(4):1170-7.
2005: Grant Langdon; Justin Wilkins; Lynn McFadyen; Helen McIlleron; Peter Smith; Ulrika S H Simonsson
Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
Antimicrobial agents and chemotherapy 2005;49(11):4429-36.
2005: Frik A Sirgel; P Bernard Fourie; Peter R Donald; Nesri Padayatchi; Roxana Rustomjee; Jonathan Levin; Giorgio Roscigno; Jennifer Norman; Helen McIlleron; Denis A Mitchison
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
American journal of respiratory and critical care medicine 2005;172(1):128-35.
2004: Grant Langdon; Justin J Wilkins; Peter J Smith; Helen McIlleron
Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2004;8(7):862-7.
2004: Karen I Barnes; James Mwenechanya; Madalitso Tembo; Helen McIlleron; Peter I Folb; Isabela Ribeiro; Francesca Little; Melba Gomes; Malcolm E Molyneux
Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study.
Lancet 2004;363(9421):1598-605.
2002: Helen McIlleron; P Wash; A Burger; Peter I Folb; P Smith
Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2002;6(4):356-61.
1999: Helen McIlleron; Gary A Gabriels; Peter J Smith; P Bernard Fourie; GA Ellard
The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1999;3(11 Suppl 3):S329-35; discussion S351-2.
1999: Goonaseelan Pillai; P Bernard Fourie; Nesri Padayatchi; Philip Onyebujoh; Helen McIlleron; Peter J Smith; Gary A Gabriels
Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1999;3(11 Suppl 3):S309-16; discussion S317-21.